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Abstract
Diversity-directed synthesis based on the cascade allylation chemistry of indigo, with its embedded 2,2’-diindolic core, has resulted
in rapid access to new examples of the hydroxy-8a,13-dihydroazepino[1,2-a:3,4-b']diindol-14(8H)-one skeleton in up to 51% yield.
Additionally a derivative of the novel bridged heterocycle 7,8-dihydro-6H-6,8a-epoxyazepino[1,2-a:3,4-b']diindol-14(13H)-one
was produced when the olefin of the allylic substrate was terminally disubstituted. Further optimisation also produced viable one-
pot syntheses of derivatives of the spiro(indoline-2,9'-pyrido[1,2-a]indol)-3-one (65%) and pyrido[1,2,3-s,t]indolo[1,2-
a]azepino[3,4-b]indol-17-one (72%) heterocyclic systems. Ring-closing metathesis of the N,O-diallylic spiro structure and subse-
quent Claisen rearrangement gave rise to the new (1R,8aS,17aS)-rel-1,2-dihydro-1-vinyl-8H,17H,9H-benz[2',3']pyrrolizino-
[1',7a':2,3]pyrido[1,2-a]indole-8,17-(2H,9H)-dione heterocyclic system.
Introduction
One of the foci of current organic synthesis is the exploration of
new chemical space, with an emphasis on significant hetero-
cyclic molecular diversity [1,2]. Direct applications of such
advances in medicinal chemistry, chemical biology and
nanochemistry should provide expanded opportunities for
helping to solve major, real-world problems. Additional to the
discovery of representatives in new chemical space must be the
technology to produce the heterocycles in a controlled, scalable
and cost-effective manner. To this end, one approach that we
have explored is to take cheap and readily available structurally
advanced starting materials and induce cascade reactions to
produce relatively complex heterocycles. For example, initial
exploratory studies on the base-induced N-alkylation chemistry
of readily available indigo (1) with functionalised alkyl halides
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Scheme 1: The synthesis of N-monoallylated indigo derivatives.
has highlighted the potential for the rapid generation of poly-
heterocyclic skeletons when the halides incorporate double or
triple bond moieties [3,4]. Thus propargyl bromide with indigo
(1) provided access to representatives of the pyrazino[1,2-a:4,3-
a']diindole, pyrido[1,2-a:3,4-b']diindole and benzo[b]indolo-
[1,2-h]naphthyridine heterocycles in one-pot, multi-step
cascade sequences [3]. These ring systems are not only of
chemical interest but biological testing revealed promising in
vitro antiplasmodial activity and anticancer activity in certain
cases [3].
While the analogous base-mediated thermal reactions of allylic
bromides with 1 at 70 °C were promising and allowed facile,
but limited, access to new 1-allyl-5'-allyloxy-3',4'-dihydrospiro-
indoline-pyrido[1,2-a]indolone derivatives and pyridoindolo-
azepino[1,2-a]indol-11(7H)-one derivatives, the reactions were
incomplete, yields were modest, and oxidative isatin byprod-
ucts were significant [4].
Thus these reactions of indigo (1) with allylic halides were
further explored, not only in an effort to gain better control over
reaction pathways, but to optimise the synthesis of known poly-
cyclic ring systems to practicable yields, and to assess other
products produced, including any new heterocyclic systems
produced.
Therefore, this manuscript describes procedures for the highly
controlled one-pot cascade reactions of indigo with variations of
the allylic bromides used and reaction times. The outcomes
included the synthesis of unprecedented heterocycles, opti-
mised procedures of some previously reported structures to now
produce synthetically useful yields, and the efficient syntheses
of additional polycyclic heterocycles. These results lead to
substantial new mechanistic insights, an assessment of the
potential to further increase structural complexity through post-
allylation ring-closing metathesis, plus new biological activity
investigations, which are now reported herein.
Results and Discussion
A range of strategies are available to potentially control reac-
tion-path selectivity in cascade pathways [5,6] but in these
indigo allylation reactions it was found that reaction tempera-
ture and reaction time were particularly important together
with the nature of the allylic bromide. A higher temperature
(85–88 °C) than that used previously was found to be optimal
with the eventual complete consumption of the indigo starting
material. At this temperature, reaction times were then explored
and the product outcomes are discussed in the context of the
times used, in this study short (5 s), medium (1 h) or long (3 h).
N-Monoallylation – short reaction time
In a typical procedure, a solution of indigo (1) in anhydrous
DMF was generated through sonication for 30 min at room
temperature and then transferred to a septum-equipped flask
which contained predried molecular sieves and caesium
carbonate under an inert atmosphere. The flask was then
plunged into a preheated oil bath (strictly 85–88 °C) and stirred
for 30 min, followed by the addition of various allylic bromides
by injection through a septum under a static nitrogen blanket
and the reaction mixture then heated at this temperature for
5 seconds (Scheme 1). This yielded the N-monoallylated
indigos 2–6 as the dominant products in yields of 37–62% as
papery blue solids. The structure about the 2,2’-double bond of
these compounds was presumed to be transoid based on the
retention of the intense blue colour which arises from the pres-
ence of at least one H-bond between the NH and carbonyl, as
well as the absence of a nOe interaction between the N-meth-
ylene and the NH present; this was confirmed by an X-ray
structure for 2. These compounds also had a significantly higher
solubility in organic solvents relative to the parent indigo
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Scheme 2: The synthesis of 8a-hydroxyazepinodiindolones.
Figure 1: The structure and X-ray crystal structure (ball and stick
representation) of azepinodiindolone 7. The corresponding ORTEP
data for 7, 8 and 9 is reported in Supporting Information File 1.
starting material. Although indigo starting material also
remained at the end of the reaction, it could be readily sep-
arated on the basis of solvent solubility.
These monoallylated compounds are of particular importance in
that the improved solubility allows for a greater range of reac-
tion solvents for subsequent reactions. Therefore, the procedure
for their synthesis was optimised by allowing a greater time for
the initial generation of the anion (1 h vs 30 min) – this resulted
in an increase in yield to 83%, 81% and 89% for the monoally-
lated indigos 2, 3 and 4, respectively.
Synthesis of azepinodiindolones – medium
reaction time
Under identical reaction conditions to those reported above,
with the exception of a one–hour reaction time after addition
of the allyl bromides, the major products isolated were new
derivatives of the fused azepinodiindolo system [5], the
8a-hydroxy azepinodiindolones 7–10 (Scheme 2). While minor
yields of these red compounds (7–10%) were obtained after
reaction for 5 s, optimal yields occurred after 1 h. Interestingly
cinnamyl bromide did not produce any of this ring system [7],
while for 1,1-dimethylallyl bromide further N-allylation was not
evident.
Analysis of the 1H NMR spectrum of 7 revealed a peak at
4.73 ppm assigned to the alcohol – this peak disappeared upon
treatment of the sample with D2O. The quaternary benzylic C8a
(Figure 1) was assigned to the peak at 81.3 ppm in the
13C NMR spectrum, downfield due to the effects of the at-
Figure 2: Dihydroazepino[1,2-a:3,4-b']diindolones from Nb-acyl-L-tryp-
tophanamides [5].
tached alcohol substituent and its benzylic/allylic nature.
Analysis of the HMBC spectra revealed strong correlations
between H9 and C8a, H8 and C8a, and a weaker correlation
between H6 and C4a. The structures of 7 (Figure 1), 8 and 9
were confirmed by X-ray crystallography analysis.
Azepinodiindolones 7 and 8 were obtained in moderate yields.
The addition of substituents in the terminal position of the allyl
substrate resulted in a lowering of yield of the analogous prod-
ucts 9 and 10, while no such product was evident from the reac-
tion with the larger cinnamyl bromide. Minor byproducts
isolated were the corresponding N-monoallylated indigos
(7–15%).
These heterocycles arise from the cyclisation of one allyl unit
onto a carbonyl, leading to the tertiary alcohol. They are deep
red in colour, probably due to the central double bond
remaining intact while one of the indigo carbonyl units has been
transformed. Theoretically, diastereomers are possible due to
the presence of the stereogenic C8a carbon and an atropiso-
meric chiral element from restricted rotation in the 7-membered
ring [8]. However, analysis of the 13C NMR spectra of these
products indicated only a single set of peaks in each case and no
evidence for a diastereomeric mixture. Presumably, the atropi-
someric rotation barrier is sufficiently low at room temperature
to allow for interconversion.
While derivatives of the azepino[1,2-a:3,4-b']diindolone
skeleton have been reported previously, albeit in a different oxi-
dation state and with notably different substitution patterns [5]
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Scheme 3: The optimal synthesis of spiro heterocycles 12–16, and spiro/polyfused ring heterocycles 17 and 18 (R2, R3 omitted for clarity in 17, 18).
Scheme 4: The synthesis of the oxa-bridged azepinodiindolone 22 from indigo and 1-bromo-3-methylbut-2-ene.
(Figure 2), they were only obtained as very minor diastereo-
meric products (ca 1% yields) from acid-catalysed cyclisation
studies on Nb-acyl-L-trypotophanamides.
Three–hour reactions of indigo with allyl bro-
mides
Analysis of the product outcomes of the corresponding 3 hour
reactions of indigo with different allyl bromides (Scheme 3)
confirmed the synthesis of the known 8H,16H-pyrido[1,2,3-
s,t]indolo[1,2-a]azepino[3,4-b]indol-17-one heterocycles 17 and
18, which arise from the addition of two allyl units with one
cyclising to form a 6-membered ring and the other to form a
7-membered ring [4]. These yields are now excellent for the
production of these reasonably complex heterocycles, around
70% for 17 and 18. Notably, the olefinic terminal position
remains unsubstituted to achieve these outcomes. The addition
of substituents to the terminal positions of the allyl reagents
(crotyl, 1,1-dimethylallyl, cinnamyl) resulted in a change in the
major product outcome to the known spiro heterocycles 14, 15
and 16, although with a decreasing absolute yield (65% to 37%)
with increasing steric presence; none of the fused azepino-
indolones (designated 19–21) analogous to 17 and 18 were
obtained. The yield of 37% obtained for the cinnamyl deriva-
tive 16 is a significant improvement on that (12%) previously
reported [4] and the analogous derivative 15 is reported for the
first time. The previously reported low yields of these spiro-
based heterocycles were accompanied by significant quantities
of indigo starting material. These reactions are also scalable at
least up to 1 gram quantities of indigo starting material to
produce a 72% yield of 17 – this is a four-fold increase in quan-
tity over the standard reactions quantities.
Additional outcomes of reaction of indigo with
allyl bromides
Interestingly, in all cases with the use of 4-bromo-3-methylbut-
ene (5 s, 1 h, 3 h), an additional novel heterocyclic derivative
was isolated in 21, 26 and 23% yields, respectively (Scheme 4).
This red compound showed the addition of two allylic systems,
with one cyclised, with the intense colour suggesting that the
central double bond was intact and with extended conjugation
present. The 13C NMR spectrum contained one peak in the
region at 177.5 ppm, corresponding to the presence of one car-
bonyl functionality. The IR spectrum was notable for the
absence of a broad absorption band in the 3300 cm−1 region,
implying the absence of an alcohol group, despite the red colour
suggesting that one of the allylic substitutions had cyclised,
most likely onto a carbonyl. Key to the structural elucidation
were NOESY experiments which showed correlations between
the aromatic H4 proton and the H6 bridgehead proton (Figure 3)
– the same H6 proton correlated strongly with one H7 and
weakly with the second H7 proton suggesting a –CH2–CH–
arrangement in a conformationally restricted ring, with the
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Figure 3: Modelled structure (Spartan 10, v1.1.0, Wavefunction Inc) of bridged indigo-tetrahydrofuran product 22. Left: top view showing the tetrahy-
drofuran ring sitting directly over the indigo skeleton (vertical), which itself is twisted from planarity. Middle: front view. Right: NOESY correlations in
support of the proposed structure (s = strong; w = weak).
Table 1: Calculated values of ΔHf of the red diindolone substrate 10 and the bridged tetrahydrofuran product 22, plus the distance between nucleo-
phile (O) and electrophile (C) in the proposed key reaction intermediate, structure 27, together with comparison data for analogous structures from 9
and 7.
C8 substitution pattern ΔHf substrate (diindolones)
kJ/mol
ΔHf cyclic aminals (bridged
tetrahydrofurans) kJ/mol
distance between (C8a)O
and C6 (Å)
2 × Me (10) 262.715 263.010 (22) 3.042 (27)
1 × Me, 1 × H (9) 289.247 295.266 3.056
2 × H (7) 338.331 351.245 3.180
weak correlation assigned to the transoid arrangement of
protons and the strong correlation to the cisoid configuration. In
addition, significant 3-bond correlations in the HMBC spec-
trum were observed between H6 and the quaternary C8 and H7
and the benzylic C8a. The downfield shift of the peak at
92.7 ppm, assigned to C8a, is consistent with the benzylic
carbon being also attached to an oxygen atom. This new hetero-
cyclic product was thus assigned as the oxa-bridged azepinodi-
indolone 22. The geometry optimised structure for 22 (Figure 3)
showed the two indolic units to be in a slightly bent orientation
to each other, with the 7-membered ring in the same curved
line. The 5-membered tetrahydrofuryl ring is disposed orthogo-
nally to the curved backbone and is in a puckered conformation,
typical of 5-membered aliphatic rings. The heterocycle is stable
at room temperature and to air and moisture. This is the first
example of the synthesis of this bridged heterocyclic skeleton.
The formation of 22 is an excellent example of the ‘gem-
dimethyl effect’ [9] whereby the presence of that moiety
enhances cyclisation [10]. This explains the formation of 22 and
the lack analogous cyclised products when the gem-dimethyl
group was absent, as evidenced by the absence of distinctive
red-coloured products by TLC analysis. Interesting in this par-
ticular reaction is the induction of the gem-dimethyl effect in
producing a bridged product from a cyclic starting material.
Further evidence in support of the bicyclic heterocycle 22
comes from analysis of computational models of the proposed
starting materials to cyclisation (i.e., alcohol 10) and the
bridged products, e.g., 22 (Table 1). The ΔHf of the gem-
dimethyl substrate 10 (262.7 kJ/mol) is remarkably similar to
the product bicycle 22 (263.0 kJ/mol) whereas the ΔHf for the
corresponding theoretical bridged products (295.3 kJ/mol and
351.2 kJ/mol) arising from cyclisation of monomethyl (9;
289.2 kJ/mol) and 8-methylene (7; 338.3 kJ/mol) starting ma-
terials respectively, are of higher energy. Further, the distance
between the proposed O-nucleophile and C6-imine electrophile
in the proposed intermediates to cyclisation (see structure 27 in
Scheme 7) is least for the gem-dimethyl compound 10
(3.042 Å) and larger for the monomethyl compound 9 (3.056 Å)
and 7 (3.180 Å).
With cinnamyl bromide, an additional variation in the product
outcome was observed in 16% yield, identified as 23
(Scheme 5) and represents a new variation on the spiro hetero-
cycle of the type exemplified by 16. This yellow compound
corresponded to the addition of two cinnamyl units, with one
cyclised to form the parent spiro system. Analysis of the
13C NMR spectrum showed the presence of peaks at 197.5 and
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Scheme 5: The reaction of indigo with cinnamyl bromide yielding two spiro-based derivatives.
Figure 4: Structural analysis of compound 23. Left: modelled structure showing the cisoid configuration of the NH and the cinnamyl substituents.
Middle: X-ray crystal structure (ball and stick representation) showing the transoid NH/C8'-phenyl substituent disposition. Right: key HMBC correla-
tions in support of the proposed structure (s = strong; w = weak). ORTEP data for 23 is given in Supporting Information File 1.
197.8 ppm, assigned to two carbonyl groups. This eliminated
the substituent pattern as defined by spiro compounds 12–16.
The C-allylated product 23 was evidenced by analysis of the
HMBC spectrum which showed a strong 3-bond correlation
between the C2 spiro carbon and the cinnamyl methylene (H1'').
Appearance of a multiplet at 2.98–3.10 ppm assigned to the
C–CH2 revealed the 2.4 ppm shift compared to the chemical
shift of deshielded O–CH2 protons in the spiro product. Another
signal appearing at 7.87 ppm, assigned to an NH, and its nOe
correlation with H7 from the aromatic ring confirmed the pres-
ence of the non-alkylated isoindoline moiety. The observation
of one set of peaks in the 13C NMR spectrum indicated the
presence of a single enantiomeric pair of isomers, and analysis
of the X-ray crystal structure (Figure 4) showed that the rela-
tive stereochemistry was either all-R or all-S. Based on these
results the cinnamyl substituent is placed in a cisoid orientation
to the isooxindolic N–H and the C8' substituent possesses a
transoid configuration. This configuration allows for the bulky
cinnamyl substituent to swing away and be on top of the
concave structure.
In summary, a bulky terminal substitution pattern in the allylic
bromide reactant is thus an important factor in determining the
eventual main product outcomes after N-monoallylation.
Mechanistic discussions
The short reaction times suggest the initial formation of mono-
allylated products followed by a second N-allylation in most
cases and cyclisation, although the exact order of these two
steps is not apparent. Evidence for the formation of the N,N'-
diallylated products was observed, e.g., by mass spectral
analysis of reaction mixtures, but such products were never
isolated. After 5 s reaction time, the red diindolone hetero-
cycles 7–10 were already produced, an indication of the ease of
the cascade processes. After 1 h reaction time, there was no evi-
dence for the presence of the monoallylindigo products, and the
spiro compounds were present in minor quantities. Instead, a
greater proportion of the red diindolones was produced. After
3 h reaction time the spiro compounds 12–16 and azepinodiin-
dolones 17–18 predominate with a corresponding loss of the
monoallylindigos and diindolones. This includes the more steri-
cally demanding cinnamyl bromide and 1-bromo-2-butene
which also gave rise to spiro heterocycles (16 and 15 respect-
ively), the latter reported here for the first time. The products
arising from oxidative cleavage, the N-allylisatins, are dimin-
ished under these optimised conditions, and appear to arise only
after longer reaction times. The proposed mechanism for the
formation of spiro derivatives 12–16 was previously reported
[4].
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Scheme 7: Proposed mechanism for the formation of 22. The order of protonation and allylation is undetermined.
Scheme 6: Proposed mechanism for the synthesis of the red diin-
dolone heterocycles and the azepinodiindolones.
Scheme 6 illustrates a tentative proposed mechanism for the
synthesis of the azepinodiindolones and the red diindolone
heterocycles through an intermediatory diallylindigo 24
(Scheme 6). Deprotonation could then produce a stabilised
ylide, thus providing a formal negative charge for subsequent
cyclisation onto the carbonyl forming the 7-membered ring. In
Path A, dehydration and cyclisation onto the activated iminium
cation 25 could form 17. Path B describes the base-induced
deprotonation to form the neutral product 26.
While dehydration of 26 could conceivably also occur
(Scheme 6), no evidence for the expected azepine product 27
was seen. An attempt to separately dehydrate 26, by reaction
with P2O5 resulted in an inseparable mixture. However, the
same compound under basic conditions (Cs2CO3) in DMF at
85–87 °C (20 min) produced 17 in 89% yield, thereby providing
evidence that compounds 7–11 (26 when Z = allyl) and
analogues could also be intermediates in the synthesis of the
azepinodiindolones as proposed in Scheme 6 (Path C).
Additionally, in support of the pathways proposed, the reaction
of N-allylindigo 2 under the typical cascade reaction conditions
for these compounds gave 17 in 59% yield and the spirocycle
12 in 8% yield.
In the case of the dimethyl allyl analogue 22, reversible proto-
nation (HCO3−) of the enamine moiety in 27 (Scheme 7) and
subsequent intramolecular cyclisation would realise the bridged
heterocycle 22, with this latter reaction promoted by the gem-
dimethyl effect.
In the case of the spiro products, an exception is the spirocycle
23 derived from cinnamyl bromide reaction with the intermedi-
ate 29 (see Scheme 8). At the O-cinnamyl stage, the formation
of two highly stabilised radicals could provide a driving force
for a 1,3-shift leading to the C-allylated structure via a ther-
mally induced homolytic cleavage of the cinnamyl unit
(Scheme 8). While direct anionic C-allylation of N-cinnamyl-
indigo may also lead to 22, steric considerations and the non-
observance of this product with other allylic bromides points to
a later intervention of a 1,3-rearrangement process.
The N-allylisatins observed [4] are likely to be formed by
oxidative cleavage processes as previously reported [4,11].
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Scheme 8: Proposed mechanism for the formation of 23 from intermediate 29.
Scheme 9: Proposed key branch points and mechanistic sinks in the base-catalysed cascade allylation reactions of indigo (1). Only parent hetero-
cyclic systems are drawn except when specific substitution patterns produce particular outcomes.
Control of the branch points in the overall base-catalysed
cascade allylation reactions with indigo is clearly important in
achieving practical synthetic outcomes (Scheme 9). The first of
these are the mono-N-allyindigos 2–6 which can branch to the
synthesis of the spiro heterocycles 12–16 (Path A – which is a
mechanistic sink). Alternatively, mono-N-allyindigos can
progress to the synthesis of the azepinodiindolones 17 and 18
(Path B – also a mechanistic sink). However, the red diin-
dolone heterocycles 7–10, accessed from the mono-N-
allylindigos, could be mechanistic intermediates and be trans-
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Scheme 10: Reaction of the spiro heterocycle 12 with Grubbs' II catalyst, and X-ray crystal structure of the novel product 31 (ball and stick
representation). ORTEP data for 31 is given in Supporting Information File 1.
formed further into the six-ring azepinodiindolones 17 and 18
or cyclised to form the bridged compound 22 (an additional
termination point – Path C).
There remains the possibility for variations outside these com-
plex sequences, for example the radical-induced 1,3-shift of a
cinnamyl moiety, likely to occur at a point buried within the
mechanistic mix illustrated in Scheme 9. Clearly, further mech-
anistic studies will be required to continue to explain the
outcomes of these cascade reactions, and therefore inform ways
to increase regioselective outcomes.
Post-allylation reactions
The products obtained from the indigo allylation reactions
provide potential further opportunities to access other hetero-
cyclic structural space. For example, the spiro heterocycle 12,
with its pendant allyl substituents, affords an ideal substrate for
a ring-closing metathesis reaction. In the event, treatment of 12
with Grubbs' II catalyst at reflux in CH2Cl2 produced not the
expected 9-membered ring, but rather the novel fused hetero-
cycle 31 in 70% isolated yield (Scheme 10). The structure,
including relative stereochemistry, was confirmed by X-ray
crystallographic analysis. This compound was formed presum-
ably after initial 9-membered ring production to give 30 in a
typical ring-closing metathesis reaction, followed by an intra-
molecular Claisen rearrangement. Attempts to induce a similar
Claisen rearrangement starting from the original spiro com-
pound 12 by heating a DMF solution from 40 °C to 110 °C
failed, with only decomposition being observed at the higher
temperatures. This suggests that the Claisen rearrangement is
being catalysed by the Ru present from the Grubbs' reagent.
This is not unexpected as there are reports of ruthenium-based
species catalysing Claisen rearrangements [7] including a
similar RCM–Claisen sequence in 2,2'-bis(allyloxy)-1,1'-
binaphthyls and O,O'-(but-2-en-1,4-diyl) binaphthols [12,13].
Additionally, examples of C2 to C3 Claisen rearrangement of
2-allyloxyindoles by related Pd catalysis have been reported
[14]. The 13C NMR spectrum of 31 showed only one set of
peaks for the molecule indicating that only one pair of enan-
tiomers was present, despite the presence of three stereogenic
atoms. This is likely to arise from the spiro starting material
being racemic, and the subsequent Claisen rearrangement being
stereospecific.
A peak at m/z 354 [M+] in the EIMS corresponds to the molec-
ular ion of the ring-closing metathesis product after elimination
of an ethylene unit. Analysis of the 1H NMR revealed the pres-
ence of a one-proton multiplet at 3.55–3.58 ppm corresponding
to H1, while gCOSY was consistent with the presence of a vinyl
substituent group. HSQC spectral evidence supported three CH2
groups, while the 13C NMR spectrum confirmed the presence of
two free carbonyls with signals at 197.9 and 201.0 ppm. From
the HMBC spectrum, a strong correlation between C8a and H2
and also between H2 and C17a through three bonds was
observed, confirming the formation of the pyrrolizidine ring
system. The proposed structure of 31 was also confirmed by
X-ray crystallography analysis.
Biological activities
In preliminary screenings for biological activity, selected com-
pounds were assessed for in vitro antiplasmodial (Plasmodium
falciparum; drug resistant K1 strain) activity [15], cell-based
anticancer activity (cell lines: NCI-H187 small cell lung cancer,
KB oral cavity cancer, and MCF-7 breast cancer) [16], and in
Beilstein J. Org. Chem. 2015, 11, 481–492.
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Table 2: In vitro antiplasmodial, anticancer, and antitubercular activity of compounds 12–14, 17, 18, 32–35, 8, 9, and 31.a
compound IC50 µg/mL (µM) or MIC µg/mL (antitubercular)
NCI KB MCF-7 antitubercular antiplasmodial
12 9.45(24.7)
– – 50.0
(131)
2.65
(6.25)
13 ntb – – nt nt
14 10.8(25.5)
11.3
(26.7)
– nt –
17 3.35(10.3)
9.71
(30.0)
– 12.5
(38.6)
3.06
(9.44)
18 nt nt – nt nt
32 5.45(29.1)
– – nt –
33 3.23(16.1)
22.4
(96.4)
– –
34 4.83(24.0)
– – 50.0
(248.5)
–
35 – – – nt –
8 13.1(35.3)
15.0
(40.6)
5.79
(15.6)
– 1.94
(5.20)
9 – 24.9(62.3)
34.7
(93.7)
– 2.97
(8.31)
31 – – – – –
Ellipticine 1.47 0.737
Doxorubicin 0.077 0.504 7.97
Tamoxifen 5.83
Rifampicin 0.025
Streptomycin 0.625
Mefloquine 0.0115
Artenimol 0.00074
a–, not active up to 50 µg/mL; bnt, not tested. NCI H187 = NCI small cell lung carcinoma, KB = KB oral cavity cancer, MCF-7 = MCF-7 breast cancer;
N-allylisatin (32), N-2-methylpropenylisatin (33), N-crotylisatin, (34), N-3-methyl-2-butenylisatin (35) [4].
vitro antitubercular activity (Mycobacterium tuberculosis) [17]
(Table 2).
Promising antiplasmodial activity was seen with the spirocyclic
compound 12 (IC50 2.65 µg/mL, 6.25 µM) and the related
indoloazepinoindol-17-one 17 in which the allylic substituents
are effectively merged (minus the ether oxygen) and embedded
in the 7-membered ring (IC50 3.06 µg/mL, 9.44 µM). While the
introduction of a methyl substituent in the allylic moiety (spiro
heterocycle 14) was detrimental to this activity, other possibili-
ties exist for substituent variation at other sites, e.g., in the
aromatic rings (starting with substituted indigo derivatives) and
at the carbonyl group, for future SAR studies. In addition, with
compounds of the non-spirocyclic type 8 and 9 good antiplas-
modial activity was also seen, with 8 being the most potent
(IC50 1.94 µg/mL, 5.20 µM) of the compounds tested here.
In order to further assess selective cytotoxicity, the toxicity of 9
towards Vero cells [18] was attempted but its autofluorescence
precluded a result being obtained. These spiro heterocycles,
indoloazepinoindol-17-one and azepinodiindolo compounds
constitute new antiplasmodial structural leads with potentially
new modes of action.
Modest cytotoxicity against all three cancer cell lines tested [18]
was observed with the azepinodiindolo compound 8 (IC50
5.79–15.0 µg/mL, 15.6–40.6 µM). Similarly the indoloazepino-
indol-17-one derivative 17 showed some activity against the
small cell lung and oral cavity cancer cell lines (IC50 3.35 and
9.71 µg/mL, 10.3 and 30.0 µM, respectively), but not against
the more refractory MCF-7 breast cancer cell line [16]. Addi-
tionally, 17 exhibited some antitubercular activity (MIC
12.5 µg/mL, 38.6 µM), providing a basis for further struc-
turally novel lead development of anti-TB compounds. The
need for such compounds is a pressing one with the develop-
ment of major mycobacterial resistance [19].
Patchy cytotoxic activity was seen with the N-substituted isatins
32, 33, and 34. Compounds of this general type, but incorpor-
ating N-arylmethyl as well as 5,7-dibromo substituents, have
Beilstein J. Org. Chem. 2015, 11, 481–492.
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given rise to potent anticancer compounds with activity prob-
ably being mediated, at least in some cases, through micro-
tubule destabilisation and inhibition of tubulin polymerisation
[20-22].
Conclusion
The search for diversity in new heterocyclic chemical space is
increasingly important in areas such as medicinal chemistry and
nanotechnology, where novel heterocyclic starting points are
urgently required. The newly established cascade allylation
chemistry of indigo provides a fertile ground for the discovery
of such heterocycles not readily available by other means, and
key to this is the ability to produce novel heterocyclic struc-
tures in one-pot in reasonable yield. We report here the optimi-
sation of the synthesis of two heterocycles, the spiro compound
14 (65%) and the fused 7-membered ring product 17 (72%) –
both these heterocycles are synthesised in one pot from a cheap
and readily available starting material and represent an excep-
tionally efficient synthesis of novel polycyclic compounds.
Further, we report for the first time the synthesis of derivatives
of these heterocycles, including those using the sterically
hindered allyl reagents with terminal methyl substituents.
The allylation reaction also provides access to new hydroxy-
lated heterocyclic derivatives of the azepinodiindolo type.
These intensely red compounds can be synthesised in one pot in
yields of up to 51% and are presumably also intermediates in
the synthesis of the indoloazepinoindol-17-ones. One of the
more interesting outcomes is the first synthesis of the bridged
compound 22, with a heterocyclic skeleton not likely to be
readily accessible by other means. As with all these reactions,
the synthesis of 22 is repeatable, and given the reliability of
outcome and complexity of this structure, a 26% yield is a rea-
sonable achievement.
Enhancement of the synthetic scope of the tandem
RCM–Claisen chemistry has been established with the produc-
tion of the new heterocyclic system 31 from the spiro com-
pound 12. Further application of this tandem methodology
offers significant potential in heterocyclic synthesis.
Promising in vitro antiplasmodial activity was indicated with a
number of the spiro, indoloazepinoindol-17-one and azepinodi-
indolo heterocycles, while the in vitro antitubercular activity of
one indoloazepinoindol-17-one compound, 17, was also of
interest.
We have reported here significant new chemistry in the cascade
reactions of indigo. This recently discovered area has the poten-
tial through other substituted alkylating agents and through
substituted indigos and variations on that skeleton, to greatly
contribute to the synthesis of a diverse array of new hetero-
cyclic compounds. Important in this area is a deeper under-
standing of the mechanisms involved and strategies for the opti-
misation of regio- and stereospecific product yields in these
one-pot reactions and further studies are continuing.
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